RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced
FDA approved blinded, multi-centric Phase-3 trial (NCTsrc6489src28) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU...Read More
Stephania Culton
